MAGE-A3 With Cell-Penetrating Domain as an Efficient Therapeutic Cancer Vaccine
Open Access
- 1 May 2014
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 149 (5) , 451-457
Abstract
The immune system has the ability to detect and eliminate tumor cells through the generation of cytotoxic T lymphocytes (CTLs), a process known as immune surveillance.1 However, cancer cells may evade this process, and immunotherapy with dendritic cells (DCs) is a relatively nontoxic alternative that may overcome elements of host immune incompetence.Keywords
This publication has 19 references indexed in Scilit:
- Dendritic Cell-Based Tumor Vaccinations in Epithelial Ovarian Cancer: A Systematic ReviewImmunotherapy, 2012
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parametersCancer Immunology, Immunotherapy, 2008
- Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic MelanomaJournal of Immunotherapy, 2008
- Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)Journal of Clinical Oncology, 2007
- The taming of the cell penetrating domain of the HIV Tat: Myths and realitiesJournal of Controlled Release, 2007
- Protein Transduction of Dendritic Cells for NY-ESO-1-Based Immunotherapy of MyelomaCancer Research, 2005
- Cross‐presentation, dendritic cell subsets, and the generation of immunity to cellular antigensImmunological Reviews, 2004
- “Translocatory proteins” and “protein transduction domains”: a critical analysis of their biological effects and the underlying mechanismsMolecular Therapy, 2003
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003